(Q44133307)

English

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

scientific article published on 23 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

object named as

D Apter

9

0 references

Xavier Castellsagué

object named as

X Castellsagué

11

0 references

object named as

F Struyf

25

0 references

Suzanne Marie Garland

16

object named as

S Garland

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Francesc Xavier Bosch José

20

object named as

F X Bosch

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

A Szarewski

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

W A J Poppe

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

S R Skinner

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

C M Wheeler

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J Paavonen

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

P Naud

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J Salmeron

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

S-N Chow

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

H Kitchener

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J C Teixeira

12

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J Hedrick

13

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

U Jaisamrarn

14

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

G Limson

15

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

B Romanowski

17

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

F Y Aoki

18

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

T F Schwarz

19

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

D M Harper

21

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

K Hardt

22

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

T Zahaf

23

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

D Descamps

24

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Lehtinen

26

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

G Dubin

27

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

HPV PATRICIA Study Group

28

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

23 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

131

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

106-116

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Prevalence of HPV infection among females in the United States

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

The use of human papillomavirus seroepidemiology to inform vaccine policy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Antigen-specific memory B cell development

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26362

21 January 2018

Identifiers

10.1002/IJC.26362

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44133307&oldid=2106943261"